Inspired by recent advances in antibody-based therapeutics to treat protein conformational neurodegenerative diseases (46–49), we hypothesized that antibodies could thwart mutant myocilin misfolding and the subsequent accumulation in the ER that confers a toxic gain-of-function and downstream pathology. Here, MYOC is linked to neurodegenerative disease.